Neurocrine Biosciences(NBIX)
Focus: Neurocrine Biosciences is a publicly traded biotechnology company headquartered in San Diego with 1,001-5,000 employees, focused on neuroscience and endocrinology therapeutics. The company is currently heavily dependent on its flagship product INGREZZA for tardive dyskinesia and related movement disorders.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
123+13 this month
Growing — net +13 jobs in 30d
84 jobs added vs 71 removed. Steady team buildout.
Should You Work at Neurocrine Biosciences?
AI assessmentNeurocrine is a solid mid-career opportunity for specialists in regulatory, clinical, or commercialization roles seeking stability and near-term growth, but long-term tenure depends on successful Phase 3 transitions before the INGREZZA LOE cliff.
Why Work Here
- Strong revenue growth trajectory ($1.5B in FY2024 to $1.9B in FY2025, +26.7% YoY) with solid profitability ($250M net income) demonstrates financial stability
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.9B
Key Products
Peak14.0yr
Flagship product accounting for 100% of current revenue; at peak lifecycle with strong Part D reimbursement but facing patent cliff in 15 years.
Help build intelligence for Neurocrine Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.